Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-927711 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: BMS-927711 (300 mg) | ACTIVE_COMPARATOR | - |
| Arm 2: BMS-927711 (600 mg) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-927711 (CGRP Antagonist) | DRUG | Capsule, Oral, 300 mg, Once, One day |
Inclusion Criteria: * Patients with migraine with or without aura who are otherwise healthy as determined by medical history, physical examination, clinical laboratory evaluations and 12-lead electrocardiogram (ECG), will be eligible * Men or women \[women of childbearing potential (WOCBP) or Women...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1 |
| Ki Health Partners. LLC | RVNC | 1 | - | Daxibotulinumtonix A |
BMS-927711 is an investigational small molecule being developed for the treatment of migraine. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with migraine to evaluate its effects during acute migraine episodes and non-migraine conditions.
BMS-927711 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for the treatment of migraine.
BMS-927711 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied for the treatment of migraine, and its safety and efficacy have not yet been established.
BMS-927711 has one completed Phase 1 clinical trial, NCT01445067, which evaluated the pharmacokinetics of the drug in patients with migraine during acute migraine and non-migraine conditions. The trial enrolled 48 participants in the United States and was active-controlled but not double-blinded.
BMS-927711 is a unique investigational compound developed by Pfizer. No alternative names for this drug have been disclosed. It is being studied specifically for the treatment of migraine and is not known to be identical to any other marketed medication.